SNDS: Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU
In this webinar, our experts provided an overview of the SNDS and the key working…
CertaraOctober 20, 2020
Best Practices for Small to Mid-Size Companies to Advance Drug Discovery Programs
Having the ability to scale with research needs is pivotal to success. Understanding when the…
CertaraOctober 12, 2020
Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy
Model-informed precision dosing (MIPD) has become synonymous with modern approaches for individualizing drug therapy, in…
CertaraOctober 12, 2020
Stay on Track and Get Some Sleep: Marketing Application Best Practices
Without careful execution and the ability to navigate unexpected challenges, marketing application submissions are prone…
CertaraOctober 7, 2020
Intro to Smart In Silico Tools to Aid in Translating In Vitro & In Vivo Studies
Safety issues account for about a quarter of the attrition in drug projects, and can…
CertaraOctober 5, 2020
Enabling Warp Speed Using the Hypervelocity Innovation Model: A Blue Print for Drug Development in Pandemics
Pharmaceutical R&D is organized around prioritized investments, delivering on assets with the greatest return of…
CertaraSeptember 28, 2020
Payment Pressures in U.S. Specialty: Status quo and outlook for future financing
To allow for the optimal positioning of your product, portfolio, or company, it is critical…
CertaraSeptember 15, 2020
New Pinnacle 21 Community Validation Engine: FDA (1907.2)
In August 2020, we released our new Pinnacle 21 validation engine “FDA (1907.2)” for preparing…
CertaraSeptember 13, 2020
